Gilead Sciences has reached a deal with several generic drugmakers to produce a cheaper version of its popular, $1,000-per-pill hepatitis C drug Sovaldi for use in developing countries.
Sep 15, 2014
not rated yet | 0
A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new on ...
Aug 27, 2014
4.4 / 5 (5) | 0